| Literature DB >> 21673449 |
Jalal Izadi Mobarakeh1, Anahita Torkaman-Boutorabi, Amir Abbas Rahimi, Shahrooz Ghasri, Reza Mohammad Ali Nezhad, Arash Hamzely, Baharak Khoshkholgh Sima, Kazuhiro Takahashi, Kazuo Nunoki, Kazuhiko Yanai.
Abstract
Histamine and calcitonin gene-related peptide (CGRP) contribute to the pain perception. The aim of the present study is to clarify the interaction of histamine and CGRP in the perception of inflammatory pain. The effects of a histamine H1 receptor antagonist (pyrilamine, i.p.), an H2 receptor antagonist (ranitidine, i.p.) and a CGRP antagonist (CGRP 8-37, i.t.) on the formalininduced pain was studied in rats. Pyrilamine and ranitidine produced a dose-dependent antinociceptive response in the first and the second phases of the formalin test. A single administration of pyrilamine (1 mg/kg, i.p.), ranitidine (10 mg/kg, i.p.) or CGRP 8-37 (10 µg/µL, i.t.) had no significant effects on the pain perception in the second phase. A combination of CGRP 8-37 and pyrilamine or ranitidine at these sub-effective doses, however, showed nociceptive response in the second phase. Moreover, a histamine (i.t.)-induced hyperalgesia was completely prevented by treatment with GGRP 8-37 at this dose. Our findings have raised the possibility that the CGRP system has interaction with histamine in the perception of inflammatory pain.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21673449 DOI: 10.2220/biomedres.32.195
Source DB: PubMed Journal: Biomed Res ISSN: 0388-6107 Impact factor: 1.203